Do patients undergoing coronary artery bypass grafting benefit from concomitant mitral valve surgery?

Moderate functional ischemic mitral regurgitation patients randomised to Coronary Artery Bypass Graft (CABG) versus CABG and down-sized ring annuloplasty

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN33897799

Enrollment

Registered

2011-06-28

Start date

2002-06-28

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional ischemic mitral regurgitation Circulatory System Mitral (valve) insufficiency

Interventions

1. Intervention group: Coronary artery bypass grafting + down-sized mitral ring annuloplasty 2. Control group: Coronary artery bypass grafting 3. Follow-up: Echocardiography 6 months, 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Moderate (grade 2+) functional ischemic mitral regurgitation in patients undergoing coronary artery bypass grafing

Exclusion criteria

Exclusion criteria: 1. Papillary muscle rupture 2. Concomitant aortic valve surgery 3. Life expectancy less than 12 months 4. Creatinine > 200 µmol/l

Design outcomes

Primary

Measure	Time frame
1. Mitral regurgitation severity 2. Left ventricular geometry and function 3. Evaluated 6 and 12 months by echocardiography	—

Secondary

Measure	Time frame
1. Mortality: in hospital and 5 years 2. New York Heart Association (NYHA) class: evaluated at 5 years 3. The following outcomes are measured 12 months postop 3.1. 6-min walk test 3.2. Minnesota questionnaire score 3.3. Brain Natriuretic Peptide (BNP)	—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026